Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy

Anti-cancer Drugs
Shiliang DongMingzhi Zhang

Abstract

Traditional chemotherapeutic drugs have shown limited clinical curative effects in antitumor therapy. The application of multidrug combination and adjuvant-drug carriers is a feasible strategy to overcome the limitations while minimizing the dosage of single drug and acquiring the synergistic effects in tumor therapy. However, the systemic toxicity, drug resistance, and tumor recurrence are still unavoidable. Here we develop core-shell nanoparticles (NPs) to encapsulate paclitaxel (PTX) and gemcitabine (GEM) for breast cancer therapy. We find that the NPs could encapsulate PTX and GEM, with an encapsulation efficiency of 96.3 and 95.13%, respectively. Moreover, the drug loading of these NPs is 2.71% (PTX) and 2.64% (GEM). Notably, the co-delivery of GEM and PTX performs enhanced anticancer effect compared with the PTX alone or GEM alone therapy at the same concentration, which indicates a synergistic effect. Moreover, encapsulation of PTX and GEM by methoxy poly(ethylene glycol)-poly(lactide-coglycolide) also shows enhanced anticancer effects (81.5% tumor inhibition) and reduced systemic toxicity in vivo compared with free drugs (65% tumor inhibition). Together with those results, co-delivery of PTX and GEM by methoxy poly(ethy...Continue Reading

References

Feb 19, 1976·The New England Journal of Medicine·G BonadonnaU Veronesi
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleftherios P MamounasNorman Wolmark
Aug 23, 2005·Reproductive Toxicology·Chidambaram PrahalathanPalaninathan Varalakshmi
Mar 28, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Thomas L'EcuyerRichard Vander Heide
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alberto BottiniAlfredo Berruti
Aug 28, 2007·Nature Reviews. Cancer·Tracy Vargo-Gogola, Jeffrey M Rosen
Sep 20, 2007·Expert Opinion on Drug Safety·Neena I MarupudiHenry Brem
Jul 26, 2008·Nature Nanotechnology·Wen JiangWarren C W Chan
Sep 12, 2008·Nature Reviews. Cancer·Jane E Visvader, Geoffrey J Lindeman
Nov 1, 2008·Cancer Research·Vincent T DeVita, Edward Chu
Dec 15, 2010·Nature Reviews. Clinical Oncology·Naoko TakebeS Percy Ivy
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J FeldmanArthur C Louie
Nov 30, 2011·Nature Reviews. Clinical Oncology·Carlos L ArteagaLuca Gianni
Dec 24, 2011·Nature Reviews. Cancer·Avi SchroederDaniel G Anderson
Jan 13, 2012·Nature Reviews. Cancer·Long V NguyenConnie J Eaves
Apr 25, 2012·Annual Review of Biomedical Engineering·Alexandre AlbaneseWarren C W Chan
May 15, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Takanori KanazawaHiroaki Okada
Jul 27, 2014·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Shuling HuangFan Yang
Jan 13, 2015·Clinical Colorectal Cancer·Bengt GustavssonFernando Gibson
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Sep 9, 2015·Nature Biotechnology·Elvin BlancoMauro Ferrari
Nov 1, 2016·Nature Nanotechnology·Amy Tarangelo, Scott J Dixon
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Oct 24, 2019·Anti-cancer Agents in Medicinal Chemistry·Sivakumar P MalliappanAbimanyu Sugumaran
Nov 7, 2019·Pharmaceutics·Kamalika SamantaSubhash C Chauhan
May 1, 2021·International Journal of Molecular Sciences·Vrinda GoteDhananjay Pal
Nov 6, 2020·International Journal of Pharmaceutics·Shweta ParohaPrashant Kesharwani

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
FACS

Software Mentioned

Graphpad

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.